LezDo TechMed vs Enlyte

By Ahmed Jemaa, Co-Founder & CEO of Medrecords AI · Updated 20 Oct 2026

If you are weighing alternatives, LezDo TechMed is built for law firms and insurers and Enlyte is built for insurers and claims organizations. The choice turns on the output you need and how each prices it. Medrecords AI adds a third option: per-page record review with cited deliverables.

Key takeaways

• LezDo TechMed is a medical record review service product for law firms and insurers. It is best known for a 2013-founded medico-legal review team.
• Enlyte is a claims technology product for insurers and claims organizations. It is best known for a large claims-technology group (mitchell, genex, coventry).
• Both publish their citation approach differently: LezDo TechMed says not stated for every entry, while Enlyte says not stated for record review.
• Pricing is the fastest filter: LezDo TechMed is tiered per-record pricing per its site and Enlyte is quote-based.
• Medrecords AI is the third option: per-page pricing, source-linked output and a drafted chronology, demand or report from the same record set.

Side by side

What is LezDo TechMed?

LezDo TechMed is a medical record review service product for law firms and insurers. Its published scope covers human and ai medical record review, chronologies and summaries. It works with medical records and describes its citation position as not stated for every entry. On security it lists founded 2013; soc 2 and hipaa noted on its site.. The company was founded in 2013; its public funding and headcount position is not published; owler lists $0 raised (owler). and 60 employees (owler); linkedin lists 201-500.. It is the better fit when buyers who want a service with human review.

What is Enlyte?

Enlyte is a claims technology product for insurers and claims organizations. Its published scope covers claims technology, clinical and network solutions. It works with claims and medical records and describes its citation position as not stated for record review. On security it lists formed from mitchell, genex and coventry; awards noted on its site.. The company was founded in Not published; its public funding and headcount position is enlyte group raised $4.98b (pitchbook); owned by stone point capital (pitchbook). and 850-1,480 employees (revelio labs and pitchbook).. It is the better fit when carriers wanting an end-to-end claims platform.

These are Medrecords AI customers, not independent reviewers. Quotes come from recorded demos and customer calls, shared with permission.

LezDo TechMed is a medical record review service product for law firms and insurers, with a scope that covers human and ai medical record review, chronologies and summaries. Enlyte is a claims technology product for insurers and claims organizations, with a scope that covers claims technology, clinical and network solutions. If those 2 descriptions point at different teams, the decision is mostly about which team owns the file, not which feature list is longer.

On pricing, LezDo TechMed is tiered per-record pricing per its site, while Enlyte is quote-based. On citations, LezDo TechMed: not stated for every entry. Enlyte: not stated for record review. Ask both for a sample where a finding opens the underlying record page, then price the same file.

Demand and drafting

LezDo TechMed covers human and ai medical record review, chronologies and summaries. Enlyte covers claims technology, clinical and network solutions. If one of those scopes is the exact output your team hands to counsel, that is the faster starting point. If both can produce it, compare the draft, the template flexibility and how many edits the attorney still has to make.

Medical records and chronologies

Ask both to process the same messy record set, including scans, duplicates, handwritten notes and missing pages. LezDo TechMed works with medical records and says not stated for every entry. Enlyte works with claims and medical records and says not stated for record review. The output that survives the source-link check is the one worth a contract.

Pricing and contract

LezDo TechMed is tiered per-record pricing per its site. Enlyte is quote-based. Neither comparison should stop at the monthly figure. Ask whether pricing is per user, case, demand, page or custom; whether revisions and human review are included; whether there are page limits or overages; and what onboarding costs in staff time.

Security and data handling

LezDo TechMed lists founded 2013; soc 2 and hipaa noted on its site.. Enlyte lists formed from mitchell, genex and coventry; awards noted on its site.. Ask for the BAA, the DPA, where data is stored, how long it is retained, and whether client data is used for model training. A security page is a starting point, not the contract.

Workflow fit

LezDo TechMed is the better fit when buyers who want a service with human review. Enlyte is the better fit when carriers wanting an end-to-end claims platform. Medrecords AI is the better fit when the job is a cited chronology plus a drafted demand, IME report or deposition summary, without a platform migration.

How to test both on one file

1. Upload the same record set to LezDo TechMed, Enlyte and Medrecords AI.
2. Open the source link behind one chronology entry or summary line in each output.
3. Compare the draft you would send to counsel, then compare the bill for the same page count.

This is the fastest way to tell a records service from a software platform. The output that survives the citation check is the one worth a contract.

Migration and switching

Switching between LezDo TechMed, Enlyte and Medrecords AI is less about data export than about trust. Ask each vendor for a named onboarding contact, a sample migration plan, the export formats and a go-live date. Then re-run 3 representative files, including one messy record set, and compare the chronology, the citations and the bill before you cancel anything. A migration that saves a subscription but loses the source trail is not a saving.

Keep the old tool live until one real file has passed the citation check. That single test tells you more than a migration deck, because it shows how the new vendor handles the records your team actually receives.

Where Medrecords AI fits

Medrecords AI is not a replacement for LezDo TechMed when you need a medical record review service platform, or for Enlyte when you need a claims technology platform. It is the third option for the record-review step: upload a record set, get a source-linked chronology and a drafted demand package, IME report or deposition summary, then review, revise and sign it.

That matters when the bottleneck is the file rather than the firm. Medrecords AI publishes its price at 10 cents per deduplicated page, falling to 5 cents at volume, with duplicates free. It reads PDFs, scans, handwriting and DICOM imaging. First case is free on us, with no page cap and no card.

Bottom line

Choose LezDo TechMed when buyers who want a service with human review. Choose Enlyte when carriers wanting an end-to-end claims platform. Choose Medrecords AI when the job is a cited chronology plus a drafted demand, IME report or deposition summary, with published per-page pricing and a free first case.

The worst outcome is buying a platform for a problem your team does not have. Run one real file through each option, open the source behind one finding, and compare the draft you would send to counsel. Decide on the output, the citations and the bill, not the demo.

More LezDo TechMed comparisons